NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals develops novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. The company's lead candidates—NRX-100 and KETAFREE (preservative-free ketamine formulations) and NRX-101 (an oral combination of D-cycloserine and lurasidone)—are in FDA review for approval.
NRX Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $169.9M market cap.
NRXP beat consensus EPS by 0.6% in Q1 FY2026, reported May 17, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
History
Spoken Alpha tracks NRXP's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 50% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXP.
$ curl https://api.spokenalpha.com/v1/companies/NRXPFAQ
Spoken Alpha indexes NRXP's earnings call transcripts at https://spokenalpha.com/companies/NRXP. Each call links to attributed speakers and parsed analyst Q&A. NRX Pharmaceuticals, Inc.'s own investor relations page is at https://ir.nrxpharma.com/.
NRX Pharmaceuticals, Inc. (NRXP) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-17 | $-0.04 | $-0.11 | +59.6% | $1.1M | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $0.18 | $-0.08 | +100.0% | $983.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.27 | $-0.52 | +48.1% | $242.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-17 | $-0.98 | $-0.53 | -84.9% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.34 | $-0.53 | +35.9% | $4.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.77 | $-0.37 | -100.0% | $4.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-10 | $-0.15 | $-0.64 | +76.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.67 | $-0.69 | +2.9% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.74 | $-0.55 | -34.5% | $8.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-28 | $-0.50 | $-0.70 | +28.6% | $8.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.07 | $-0.11 | +36.4% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.12 | $-0.14 | +14.3% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.14 | $-0.14 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.11 | $-0.10 | -10.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.21 | — | — | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.53 | — | — | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.40 | — | — | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-6.51 | $0.00 | — | $0 | — | — | EODHD |
Source: EODHD. NRXP reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.74 | $2.74 | +0.1% | +0.6% | +2.3% |
| Q4 FY2026 | $2.98 | $2.84 | +4.8% | +3.0% | +0.4% |
| Q3 FY2026 | $3.05 | $2.81 | +8.5% | -7.1% | -7.8% |
| Q2 FY2026 | $2.80 | $2.79 | +0.4% | +2.2% | +4.9% |
| Q1 FY2025 | $2.94 | $2.79 | +5.4% | +3.3% | +4.2% |
CEO since 2022 • 10/16 beats (63%) • guidance suspended Q3 FY2026
| Q4 FY2025 |
| $2.87 |
| $2.80 |
| +2.4% |
| -4.8% |
| -2.4% |
| Q3 FY2025 | $3.02 | $3.05 | -1.1% | -3.3% | -1.1% |
| Q2 FY2025 | $3.13 | $2.88 | +8.6% | +0.2% | -1.7% |
| Q1 FY2024 | $2.96 | $3.00 | -1.3% | -2.7% | -5.5% |
| Q4 FY2024 | $3.39 | $3.00 | +13.1% | -6.7% | -4.8% |